Priorities and expectations of patients attending a multidisciplinary interstitial lung disease clinic
- PMID: 32803876
- DOI: 10.1111/resp.13913
Priorities and expectations of patients attending a multidisciplinary interstitial lung disease clinic
Abstract
Background and objective: The significant and progressive morbidity associated with ILD mean that patients often struggle with the impact of this disease on their QOL and independence. To date, no studies have investigated the importance of multidisciplinary care on patient experience in ILD. We aimed to determine the expectations and priorities of patients attending a tertiary referral centre multidisciplinary ILD clinic. In particular, we sought to learn how important the multidisciplinary element of the clinic was to patients and which aspects of the clinic were most valued.
Methods: An 18-item patient questionnaire was developed in conjunction with expert physicians and specialist nurses involved in the ILD clinic and sent to all patients on the centre's ILD registry at the time of the study (n = 240). Patients rated the importance of different aspects of their experience of attending the clinic. Data collected were analysed using descriptive statistics. Comparisons across disease severity were made using two-sided Z-tests for independent proportions.
Results: A total of 100 respondents comprised the study group. Almost all respondents valued the multidisciplinary aspect of the clinic. Obtaining an accurate diagnosis and improving their disease understanding was most important to respondents. The importance of the ILD specialist nurse for both education and support increased with worsening disease severity.
Conclusion: Our results suggest that a multidisciplinary approach to the management of ILD with additional focus on patient education, as well as tailoring care to disease severity, is a plausible pathway to improving the patient experience with ILD.
Keywords: interstitial lung disease; pulmonary fibrosis; quality of life; rare lung disease.
© 2020 Asian Pacific Society of Respirology.
Comment in
-
A closer look at the multidisciplinary interstitial lung disease clinic: Who, what and how.Respirology. 2021 Jan;26(1):12-13. doi: 10.1111/resp.13936. Epub 2020 Sep 3. Respirology. 2021. PMID: 32882745 No abstract available.
References
REFERENCES
-
- Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2006; 174: 810-6.
-
- Kim DS, Collard HR, King TE Jr. Classification and natural history of idiopathic interstitial pneumonias. Proc. Am. Thorac. Soc. 2006; 3: 285-92.
-
- Idiopathic Pulmonary Fibrosis Clinical Research Network; Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012; 366: 1968-77.
-
- King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2083-92.
-
- Richeldi L, Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y et al.; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2071-82.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical